EMA Authorised: Stoboclo (denosumab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA authorised Stoboclo (denosumab) by Celltrion Healthcare Hungary Kft. for osteoporosis, including postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• STOBOCLO (DENOSUMAB-BMWO)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis, Postmenopausal;Osteoporosis;Bone Resorption. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 14/01/2026